Heaven, it sure ain't a pretty looking chart to say the least. But I'm not surprised. I mean, "normal", healthy stocks just don't go up like 50% or more a day for a few days based largely on nothing (no big partner like google saying they're taking a 30% stake in company XYZ) or no real news like, "Our new widget-magic product just got the prelim one yr sales numbers and we can't make product or keep it on the shelf fast enough" or of course in the field of bio/pharma the GOLDEN GOOSE would be an FDA APPROVAL, but this company is miles and yrs away from even that possibility IMHO. A final FDA approval is one of the most daunting and coveted things to ever be achieved- and about 1 to 2% of new drugs/invasive major products ever achieves it. That's an easily verifiable stat doing some simple google searching. It's EXPENSIVE as heck, often running min of several hundred $million dollars and sometimes as high as one $Billion dollars to get a product through the FDA final trials, submission, etc. A typical FDA final submit can run 100 THOUSAND pages- I was stunned when I first read that. It's staggering to even think about. I mean, is the tax code even that many pages? You can imagine the staff, expertise it takes to write/compile a tomb like that. That's why big pharma and others have entire staffs (40 to 100 full time) on a single product line would not be unusual in the slightest- Ph.D's, regulatory specialists, engineers from various areas of expertise, bio-med Masters or Ph.D holders, usually several M.D. or university level researchers, etc. It's daunting to say the least and expensive and timely as all get out. It's why major pharma and others worry so much about having a "deep" and full "pipeline" of drug or med candidate products. They know that only say 5 out of 100 will ever see the light of day at the other end of the gauntlet. Of those, they "hope" they hit it big with one blockbuster. It takes one Lipitor for every 100 "duds" they have. Or it takes one new "stent" (recent is a drug coated stent) to be on patent and keep a company alive for the next 10 yrs and fund all the next R&D off their big seller- Abbott, Guidant, etc. Bio-med is one of the toughest fields of tech to play in- it's brutal and for the big-boy-pants players for sure. Little guys can get crushed like a bug from big players with deep pockets- it's the sad, but true reality of the field. MONEY, cold hard cash, and lots of it is key item number one. At this point, my opinion is that's BHRT's biggest problem. You can have the greatest potential idea/widget in the world- but if you can't attract capital, and in bio-med, boat loads of it, you're usually done. BHRT's capital seems to be drying up. Their cash position on the last few SEC reports has been dismal. Not sure how they make it down the gauntlet at this point?
